

## Reference list

# CliniMACS<sup>®</sup> CD8-Depletion System

## Contents

- A) *CD8-depleted donor lymphocyte infusion (DLI) using the CliniMACS CD8 Depletion System*
- B) *CD4/CD8-depleted DLI using the CliniMACS CD4/CD8 Depletion System*
- C) *CD8-depleted DLI—other depletion methods*
- D) *CD8 depletion for graft engineering*

### A) CD8-depleted donor lymphocyte infusion (DLI) using the CliniMACS CD8 Depletion System

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.

*Meyer RG, Wagner EM, Konur A, Bender K, Schmitt T, Hemmerling J, Wehler D, Hartwig UF, Roosnek E, Huber C, Kolbe K, Herr W.*

Bone Marrow Transplant. 2010 Apr;45(4):668-74. Epub 2009 Aug 17.

Long-Term Persistence of Functionally Altered GPI-Anchor Negative T-Cell Subsets After Alemtuzumab-Based T-Cell Depleted Hematopoietic Stem Cell Transplantation.

*Wagner EM, Lay AN, Schmitt T, Hemmerling J, Wolff D, Huber C, Herr W, Meyer RG.*

Blood. Nov 2009; 114: 2438.

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.

*Meyer RG, Wagner EM, Konur A, Bender K, Schmitt T, Hemmerling J, Wehler D, Hartwig UF, Roosnek E, Huber C, Kolbe K, Herr W.*

Bone Marrow Transplant. 2010 Apr;45(4):668-74. Epub 2009 Aug 17.

Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

*Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.*

Transplantation. 2009 Dec 15;88(11):1312-8.

Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

*Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanesi M, Longoni P, Gandola L, Lombardo C, Corradini P.*

Blood. 2009 May 7;113(19):4771-9. Epub 2009 Feb 11.

CD8-depleted DLI convert mixed to full donor T-cell chimerism and replenishes the CD52-positive T-cell pool after alemtuzumab-based T-cell depleted allo-transplantation

*Meyer RG, Wagner EM, Lay AF, Schmitt T, Hemmerling J, Hartwig UF, Wehler D, Bender K, Huber C, Herr W.*

BMT. 2009 Mar;43 Suppl 1:O406

**Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.**

*Orti G, Peggs K, Thomson K, Morris E, Lowdell M, Mackinnon S, Chakraverty R.*  
Blood. 2008 Nov;112:2203

**CD8-Depleted Donor Lymphocyte Infusions Convert Mixed into Complete Donor T-Cell Chimerism after T-Cell Depleted Allogeneic Stem Cell Transplantation.**

*Meyer RG, Wagner EM, Schmitt T, Bender K, Hartwig UF, Huber C, Kolbe K, Herr W.*  
Blood. 2008 Nov; 112:2160

**Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.**

*Wagner EM, Lay AN, Wenzel S, Schmitt T, Hemmerling J, Konur A, Bender K, Huber C, Herr W, Meyer RG.*  
Blood. 2008 Nov; 112:1182

**CD8-Depleted Donor Lymphocyte Infusions Can Improve Both T- and B-Cell Reconstitution after Allogeneic Stem Cell Transplantation from Haploidentical Family Donors**

*Dodero A, Carniti C, Raganato A, Vendramin A, Di Terlizzi S, Farina L, Spina F, Fossati bellini F, Milanese M, Longoni P, Gandola L, Lombardo C, Corradini P.*  
Blood. 2008 Nov;112:354

**Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).**

*Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M, Kunzmann V.*  
Bone Marrow Transplant. 2008 Apr;41(7):643-50.  
Epub 2007 Nov 26.

**Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.**

*Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A, Hartwig UF, Wehler TC, Ullmann AJ, Gentilini C, Uharek L, Huber C, Kolbe K, Herr W.*  
Blood. 2007 Jan 1;109(1):374-82. Epub 2006 Aug 29

**Clinical-Scale Combined CD4/CD8 Depletion for Donor Innate Lymphocyte Infusion (DILI).**

*Kunzmann V, Smetak M, Weissinger F, Birkmann J, Einsele H, Wilhelm M.*  
Blood. 2006 Nov;108:3657

**CD8-Depleted Donor Lymphocyte Infusions Can Boost Immune Reconstitution after Haploidentical Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen.**

*Corradini P, Raganato A, Carniti C, Carrabba M, Lucia F, Montefusco V, Milani R, Milanese M, Longoni P, Zorzan E, Gandola L, Lombardo C, Dodero A.*  
Blood. 2006 Nov;108:3138

**Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.**

*Meyer RG, Britten CM, Konur A, Bender K, Wehler D, Hartwig U, Wehler TC, Gentilini C, Uharek L, Huber C, Kolbe K, Herr W.*  
Blood. 2005 Nov;106(11):297

**Improved Immune Reconstitution Following Pre-Emptive CD8-Depleted Donor Lymphocyte Infusions (DLI) after Haploidentical Stem Cell Transplantation (SCT) Using a Reduced-Intensity Conditioning (RIC) Regimen.**

*Corradini P, Raganato A, Carrabba M, Gandola L, Lombardo C, Carniti C, Farina L, Milani R, Dodero A.*  
Blood. 2005 Nov;106:2908

**Campath-1H-Based Reduced-Intensity Conditioning Followed by Allogeneic Blood Stem-Cell Transplantation and Preemptive CD8-Depleted Donor Lymphocyte Infusions.**

*Meyer R, Wehler D, Wehler TC, Britten CM, Burchardt A, Hartwig U, Huber C, Kolbe K, Herr W.*  
Blood. 2004 Nov;104:5069

## **B) CD4/CD8-depleted DLI using the CliniMACS CD4/CD8 Depletion System**

**Clinical-scale single-step CD4+ and CD8+ cell depletion for donor innate lymphocyte infusion (DILI).**

*Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M, Kunzmann V.*  
Bone Marrow Transplant. 2008 Apr;41(7):643-50.  
Epub 2007 Nov 26.

**Clinical-Scale Combined CD4/CD8 Depletion for Donor Innate Lymphocyte Infusion (DILI).**

*Kunzmann V, Smetak M, Weissinger F, Birkmann J, Einsele H, Wilhelm M.*  
Blood. 2006 Nov;108:3657

## C) CD8-depleted DLI—other depletion methods

**Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.**

*Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J.*  
Blood. 2002 Jun 15;99(12):4610-7

**Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.**

*Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.*  
Biol Blood Marrow Transplant. 2002 8(11):625-32

**Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.**

*Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, Beguin Y.*  
Haematologica. 2002;87:78-88

**Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.**

*Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S.*  
Biol Blood Marrow Transplant 2001;7(10):568-75

**Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.**

*Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.*  
Blood. 1998 May 15;91(10):3671-80

**CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.**

*Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R.*  
Blood. 1995 Dec 1;86(11):4337-43

**Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.**

*Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, et al.*  
Transplantation. 1994 Jan;57(1):82-7

**Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.**

*Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J.*  
Blood. 1990 Jul 15;76(2):418-23

## D) CD8 depletion for graft engineering

**Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.**

*Willems E, Baron F, Baudoux E, Wanten N, Seidel L, Vanbellinghen JF, Herens C, Gothot A, Frère P, Bonnet C, Hafraoui K, Vanstraelen G, Fillet G, Beguin Y.*  
Leukemia. 2009 Mar;23(3):608-10. Epub 2008 Sep 18. No abstract available.

**Nonmyeloablative Stem Cell Transplantation with CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Trial.**

*Willems E, Castermans E, Baron F, Baudoux E, Wanten N, Bonnet C, Hafraoui K, Frère P, Fillet G, Beguin Y.*  
Blood. 2005 Nov;106:1075

**T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.**

*Baron F, Schaaf-Lafontaine N, Humblet-Baron S, Meuris N, Castermans E, Baudoux E, Frere P, Bours V, Fillet G, Beguin Y.*  
Transplantation. 2003 Dec 27;76(12):1705-13

**Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update.**

*Baron F, Frere P, Baudoux E, Schaaf-Lafontaine N, Fillet G, Beguin Y.*  
Haematologica. 2003 Jul;88(7):835-7



Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact. The CliniMACS<sup>®</sup> System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS<sup>®</sup> MicroBeads are for research use only and not for use in humans. MACS and CliniMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH. Copyright ©2011 Miltenyi Biotec GmbH. All rights reserved.